Autolus Therapeutics will announce 2024 financial results on March 20, 2025, followed by a conference call.
Quiver AI Summary
Autolus Therapeutics plc, a biopharmaceutical company focused on next-generation programmed T cell therapies, announced that it will release its fourth quarter and full year 2024 financial results on March 20, 2025, before US markets open. A conference call and webcast with management will take place at 8:30 am EDT to discuss the results and provide a business update, with participants required to pre-register for dial-in details. The company, which has developed the FDA-approved product AUCATZYL and a pipeline targeted at cancer and autoimmune diseases, uses advanced T cell programming technologies to create more effective therapies. Further information can be found on their website.
Potential Positives
- Autolus Therapeutics will be releasing its fourth quarter and full year 2024 financial results, signaling transparency and commitment to shareholder communication.
- The upcoming conference call provides stakeholders an opportunity for real-time engagement with management regarding the company's financial performance and future outlook.
- The company has an FDA approved product, AUCATZYL, reinforcing its position in the market and demonstrating regulatory validation of its technology.
- Autolus is actively developing a pipeline of product candidates, indicating continued innovation and potential growth in their therapeutic offerings.
Potential Negatives
- None
FAQ
What are Autolus Therapeutics' upcoming financial results release dates?
Autolus Therapeutics will release its fourth quarter and full year 2024 financial results on March 20, 2025.
How can I participate in the Autolus conference call?
Participants should pre-register using the designated link to receive dial-in numbers and a personal PIN for the conference call.
What time is the Autolus conference call scheduled?
The conference call will take place at 8:30 am EDT/12:30 pm GMT on March 20, 2025.
Where can I access the Autolus webcast?
The audio webcast and replay will be available on the events section of Autolus' website.
What is Autolus Therapeutics specialized in?
Autolus Therapeutics focuses on developing next-generation T cell therapies for cancer and autoimmune diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AUTL Hedge Fund Activity
We have seen 50 institutional investors add shares of $AUTL stock to their portfolio, and 59 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 3,639,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $8,551,650
- CANDRIAM S.C.A. added 3,191,401 shares (+inf%) to their portfolio in Q4 2024, for an estimated $7,499,792
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,950,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,932,500
- STEMPOINT CAPITAL LP removed 2,616,602 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,149,014
- AVORO CAPITAL ADVISORS LLC removed 2,435,036 shares (-19.7%) from their portfolio in Q4 2024, for an estimated $5,722,334
- ARMISTICE CAPITAL, LLC added 2,328,000 shares (+33.9%) to their portfolio in Q4 2024, for an estimated $5,470,800
- FMR LLC removed 2,141,603 shares (-12.0%) from their portfolio in Q4 2024, for an estimated $5,032,767
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2024 financial results and operational highlights before open of US markets on Thursday, March 20, 2025.
Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit
www.autolus.com
Contact:
Amanda Cray
+1 617-967-0207
[email protected]
Olivia Manser
+44 7780 471 568
[email protected]
